Mumbai 400072, India
+91-90045 60540
info@omnisciencecapital.com

OmniScience Capital introduces a New Asset Class Beyond Mutual Funds on the smallcase platform

Science of Alpha from Safety

OmniScience Capital introduces a New Asset Class Beyond Mutual Funds on the smallcase platform

OmniScience smallcases bring the exclusive HNI strategies based on Scientific Investing to All

 

Mumbai, Jan 21, 2020: OmniScience Capital, a SEBI-registered Investment Adviser, has partnered with smallcase, a fintech investment platform, to bring a new asset class OmniScience smallcase. OmniScience smallcases are based on its proprietary Scientific Investing framewok which aims to “Enhance Safety, Enhance Returns”.

Until now, OmniScience’s long-only, PMS/AIF-style, strategies were exclusively available to HNI (High Net Worth Investors) due to high minimum ticket sizes required for advising their portfolios. With the highly sophisticated, fintech capabilities of the smallcase platform it is now possible to make those strategies accessible to all investors at much lower ticket sizes, starting at INR 5000/- in a fully compliant manner and with zero paperwork.

While the core strategies of OmniScience Capital are now available at ticket sizes below INR 100,000/-, many more thematic ideas and SIP (systematic investment plan) portfolios are available to all investors. These strategies are developed and advised by OmniScience Investment Adviser, the advisory division of OmniScience Capital registered with SEBI.

“OmniScience smallcases are a new asset class beyond mutual funds. The reason I call it a new asset class is these baskets of stocks, except for our core strategies and some thematics, are much more concentrated than a portfolio from a typical mutual fund, PMS (Portfolio Management Services), AIF (Alternative Investment Funds) or PAS (Portfolio Advisory Services). This makes it a higher-risk, higher-reward asset class compared to mutual funds and PMSes while providing much more safety compared to investing in single stocks. The OmniScience smallcases provide exposure to multiple stocks simultaneously benefiting from below-the-radar, innovative, disruptive themes with exponential growth opportunities, which are available at significant discount to their intrinsic values.”, said Dr. Vikas V Gupta, CEO & Chief Investment Strategist, OmniScience Capital.

OmniScience smallcases allow investors to configure their portfolios with several interesting investment themes as satellite allocations besides their core portfolio allocations. OmniScience smallcases can also be used for SIP (Systematic Investment Plan) allocations to allow the investor portfolios to benefit from market fluctuations.

“We are glad to launch OmniScience strategies on the smallcase platform. This launch will allow two new group of investors to have access to these exclusive strategies. One the investors with small investment corpuses who could not invest earlier in the Scientific Investing strategies of OmniScience Capital because of the large minimum ticket sizes. The second group is the HNI investors who want to use their existing broking and demat accounts and want a zero-paperwork, fully online experience. We think this will make the experience of our customers and partners much more richer in all senses of the term.”, said Ashwini Shami, EVP & Portfolio Manager, OmniScience Capital.

“smallcase is a brilliant platform which makes the whole ecosystem of investors, brokers, advisors and distributors frictionless and efficient. The best part is that it is fully compliant with the latest SEBI guidelines and regulations. We plan to continue growing our products and investor engagement with this platform.”, said Dr. Gupta.

About OmniScience Capital: OmniScience Capital is a Global Investment Management firm focused on global equity investments, both, US and Indian equities, empowered by its proprietary Scientific Investing philosophy. Scientific Investing creates a SuperNormal Portfolio designed to survive and thrive through uncertainties, delivering optimal “Return on Safety". Founded by a team of IITians with MBAs and PhDs from premier global institutes with a goal to “Enhance Safety, Enhance Returns”.

To know more about OmniScience smallcase, visit:

Omnisciencecapital.com/smallcase

AND

Omniscience.smallcase.com

 

For further information, please contact:

Ashwini Shami | +91 98921 40540 | ashwini.shami@omnisciencecapital.com

Download PDF version

Disclaimer:

Omniscience Capital Advisors Private Limited (Omniscience Investment Advisers) is a SEBI registered Investment Advisory firm with registration no. INA000007623.

Equity investments are subject to market risks. Global investments are subject to currency risk, country risk and other risk factors. Please read all related documents carefully. An investor should consider the investment objectives, risks, and charges & expenses carefully before taking any investment decision. Wherever there is the potential for profit there is also the possibility of loss. Therefore, investors may lose capital in markets. Past performance is not necessarily indicative of future results. This is not an offer document. This material is intended for educational purposes only and is not an offer to sell any services or products or a solicitation to buy any securities mentioned or otherwise. Any representation to the contrary is not permitted. This document does not constitute an offer of services in jurisdictions where the company does not have the necessary licenses.

Performance is based on the investments done in portfolios with proprietary money. The performance numbers are pre-expense and unaudited. Global portfolios are maintained by an independent global custodian and the performance is calculated based on the portfolio holdings. India portfolios are maintained by Orbis Financial Corporation ltd, an independent, SEBI registered custodian and fund accountant; performance is based on the NAV maintained by the fund accountant. All benchmark returns and global portfolio returns are price returns starting from May 1, 2020. Beta and Standard deviation are calculated based on daily returns since inception. Individual returns of Clients for a particular portfolio may vary significantly from the mentioned model portfolio performances and the performance of the other portfolios. No claims may be made or entertained for any variances between the performance depictions and individual portfolio performance. The data is provided as an illustration of the behavior of the strategy under different market conditions. Reader should not use it to form an opinion about the future returns from the strategy. No express or implied guarantees or warranties about the accuracy and/or completeness of the performance are being made and OmniScience Capital shall have no liability for any damages, claims, losses or expenses. Neither the investment adviser nor its Directors or Employees shall be in any way liable for any variations noticed in the returns of individual portfolios.

Our discussion may include assumptions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual outcomes to differ materially. We assume no obligation to revise or publicly release any revision to these forward-looking statements in light of new information or future events. No guarantee can be given about the accuracy and/or completeness of the data, Omniscience makes no warranties or representations, express or implied, on the products and services offered. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or services. The information relating to any company or economic trends herein is derived from publicly available sources and no representation as to the accuracy or completeness of such information can be made. We may have recommended stocks, or stocks in the mentioned sectors to clients, including having personal exposure.

This communication is confidential and is intended solely for the addressee. This document and any communication within it are void 30-days from the date of this presentation. It is not to be forwarded to any other person or copied without the permission of the sender. Please notify the sender in the event you have received this communication in error.

 

 

 

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *